Onyx's higher marketing expenses for Kyprolis seen as money well spent
This article was originally published in Scrip
Onyx Pharmaceuticals won't offer sales projections for its multiple myeloma drug Kyprolis (carfilzomib), which won accelerated US FDA approval on 20 July for patients who failed treatment with at least two prior therapies (scripintelligence.com, 23 July 2012), but stock analysts offered their own opinions on the drug's value after the firm announced its second quarter 2012 financial results.
You may also be interested in...
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.